Prevalence of Group A b-Hemolytic Streptococcus Among Children with Tonsillopharyngitis in Kyrgyzstan: The Difficulty of Diagnostics and Therapy.
OBJECTIVE
Rheumatic fever (RF) is well known disease as a result of frequent complication of the group A b-hemolytic streptococcal (GABHS) tonsillopharyngitis, have noticeably grown for the last 15 years among young generation in the Kyrgyz Republic. It is important to hold a study about the prevalence of RF and GABHS and their susceptibility to antibiotics in the Kyrgyz Republic.


METHODS
We have studied 200 children with chronic tonsillopharyngitis at the National Center of Pediatrics and Child Surgery in Bishkek (the Kyrgyz Republic) from August till September 2008. 188 (48 out of them are with RF) out of total 200 children are Kyrgyz and 12 are Russian (2 out of them are with RF). 111 out of total are female (34 out of them are with RF) and 89 are male (17 out of them are with RF). The average age of the subjects is 10.9±6.0 (from 3 to 17 years old). The presence of GABHS was assessed using two ways: by the rapid antigen detection test (RADT) for outcrop of streptococcus antigen in smear from mucosal surface of tonsils, and by bacterial culture analysis (BA). RADT was used to determine its specificity and sensitivity in order to recommend practitioners its further wide use. Furthermore, the discovered culture of GABHS have been investigated on susceptibility to antibiotics by disc-diffusion method. RESEARCH RESULTS: GABHS antigen was positive in 72 (36.0 %) subjects from RADT and in 80 (40.0%) subjects from BA out of 200 total subjects. In the patients with RF (n=51), GABHS was positive in 18 (35.2%) subjects by RADT and in 24 (47.0%) subjects by BA. In the subjects without RF (n=149), GABHS was positive in 54 (36.2%) subjects by RADT and in 56 (37.5%) by BA. Among 80 GABHS positive results sensitive to antibiotics were: to penicillin only 10 (12.5%), to ampicillin-29 (36.2%), to amoxicillin-36 (45.0%), to ceftriaxon - 31 (38.7%), to roxithromycin - 21 (26.2%), to erythromycin- 19 (23.7%). It is noted that 21 (26.2%) GABHS positive results were absolutely resistant for all these tested antibiotics. RADT showed that its specificity is 85% as well as its sensitivity is equal to 67.5%.


CONCLUSIONS
In this study the sensitivity of RADT was low; therefore, the negative results of RADT don't exclude presence of GABHS. High prevalence of GABHS antigen demonstrates not only in patients with RF, but also among healthy children (without RF) of the Kyrgyz Republic. The high prevalence of GABHS at children with RF (47.0%), probably, presents a low sensitivity to antibiotics and irregular secondary prophylaxis. Significant presence of GABHS among healthy children (37.5%) requires improvement of primary prevention to prevent further spread of RF and Rheumatic Heart Disease (RHD) in the country.
Institute of Medical Science, St. Marianna University, Kawasaki, Japan.
Nazgul A
NA
Omurzakova
Yoshihisa
Y
Yamano
Guli M
GM
Saatova
Mayramkan S
MS
Alybaeva
Kusuki
K
Nishioka
Toshihiro
T
Nakajima
J Antimicrob Chemother. 1991 Feb;27 Suppl A:75-82
1827105
JAMA. 1981 Oct 16;246(16):1790-5
6792379
Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi. 2003;14(1):9-16
14984302
Pediatr Infect Dis J. 1996 Aug;15(8):678-82
8858671
J Fam Pract. 2006 Dec;55(12):S1-11; quiz S12
17137534
Pediatr Infect Dis J. 1991 Oct;10(10 Suppl):S68-71
1945601
Braz J Otorhinolaryngol. 2006 Sep-Oct;72(5):587-91
17221049
J Antimicrob Chemother. 1989 Aug;24(2):227-33
2676941
Clin Drug Investig. 1997 Jun;13(6):338-44
27519495
Mol Med Rep. 2008 Nov-Dec;1(6):869-74
21479499
Pediatrics. 2000 Feb;105(2):E19
10654979
World Health Organ Tech Rep Ser. 2004;923:1-122, back cover
15382606
J Antimicrob Chemother. 1996 Jan;37(1):133-8
8647754
Clin Infect Dis. 2002 Jul 15;35(2):113-25
12087516
Chemotherapy. 1988;34(6):512-8
3243093
Int J Rheum Dis. 2009 Jul;12(2):79-83
20374323
Emerg Med J. 2006 Jan;23(1):32-4
16373800
Ann Emerg Med. 1995 Mar;25(3):390-403
7864482
N Engl J Med. 2007 Aug 2;357(5):439-41
17671252
Scand J Infect Dis. 1996;28(5):497-501
8953681
J Pediatr. 1986 Sep;109(3):531-7
3091801
Lancet Infect Dis. 2003 Apr;3(4):191-200
12679262
Antimicrob Agents Chemother. 2000 Jun;44(6):1453-7
10817692
Jpn Circ J. 1986 Dec;50(12):1241-5
3820534
Clin Infect Dis. 2001 Jun 15;32(12):1798-802
11360224
BMJ. 1993 May 1;306(6886):1170-2
8499823
Lancet. 1990 Nov 10;336(8724):1167-71
1978035
Lancet Infect Dis. 2005 Nov;5(11):685-94
16253886
Am J Dis Child. 1987 Feb;141(2):224-7
3101484
Circulation. 1993 Oct;88(4 Pt 1):1964-72
8403347